Predictive or prognostic test: why does it matter?
The Oncotype DX Breast Recurrence Score® test is the only test validated as both prognostic of disease outcome and predictive of chemotherapy benefit in HR+, HER2- early invasive breast cancer patients3-4,9,11. Validation of the Oncotype DX test was conducted according to published standards with a formal test of interaction from a clinical trial where patients were randomized to treatment group1,4,11. Other multigene assays and clinical-pathologic features have not provided evidence for chemo-prediction.12-14
